AACR 2024
Apr 5 - 10, 2024 | San Diego, CA
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
The Discovery of ARV-393, a Potent, Orally Bioavailable BCL6-Targeting PROTAC® for the Treatment of NHLD Sherman et al.